Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC

This is a prospective, single-arm, investigator-initiated clinical study designed to evaluate the safety and efficacy of lenalidomide in combination with targeted therapy and immunotherapy in patients with advanced hepatocellular carcinoma (HCC) who have experienced disease progression after multiple lines of systemic treatment. Eligible patients must have received at least two prior lines of systemic therapy, including both targeted therapy and immune checkpoint inhibitor (ICI)-based treatment, and must have previously achieved clinical benefit from their most recent treatment regimen before

Trial Details

NCT ID
NCT07639138
Phase
PHASE2
Sponsor
Shunda Du
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Lenalidomide
  • Targeted Therapy
  • Immune Checkpoint Inhibitors
Locations (sample)
  • Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China, China|39.9075,116.39723

Key Eligibility Criteria

  • Age ≥18 years and ≤75 years; 2. Clinically or pathologically diagnosed hepatocellular carcinoma (HCC); 3. Unresectable, locally advanced, or metast…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →